ZEISS fundus imaging device receives NMPA approval in China

The device is outfitted with fluorescein angiography and live infrared imaging capabilities. Image credit: ZEISS Medical Technology

ZEISS Medical Technology’s fundus imaging device CLARUS 700 has received National Medical Products Administration (NMPA) approval in China.¹ The device, which utilizes fluorescein angiography, will allow eye care providers in China to capture ultra-widefield, high-resolution images of the retina, according to a news release.

“ZEISS CLARUS 700 represents a major step forward in retinal imaging," said Anuj Kalra, head of Chronic Disease Management at ZEISS, in the release. "By seamlessly integrating ultra-widefield fluorescein angiography imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow."

The advanced retinal imaging system captures 133 degrees in a single image and up to 267 degrees with multiple images, and allows for the diagnosis and monitoring of retinal diseases through fluorescein angiography and live infrared imaging capabilities. The device’s camera also includes features such as PrecisionFocus, QuickCompare, and AutoBright to allow for quicker viewing of images. PrecisionFocus allows for honing in on regions of interest in the eye quickly, with QuickCompare allowing pathology changes to be compared over past patient visits and AutoBright for reducing image analysis and adjustment times.¹ The device also utilizes true color imaging, which allows for images to be separated into red, green, and blue channel categories, enhancing the visual contrast of details in certain layers of the retina.²

“Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients,” says Maxwell Liu, head of Sales and Services at ZEISS Medical Technology China, in the release.

ZEISS also provides its ZEISS Glaucoma Workplace, a software that is compatible with CLARUS, CIRRUS, and HFA3 devices. The software provides a summary of a patient’s detected progression via the Structure-Function Guided Progression Analysis (GPA) overview that shows areas where changes in patient data from CIRRUS, HFA, fundus images, and intraocular pressure are detected.³

References:

1. ZEISS CLARUS 700 receives NMPA approval in China. News release. ZEISS. June 5, 2025. Accessed June 9, 2025. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2025/zeiss-clarus-700-approval-china.html

2. ZEISS CLARUS 700. ZEISS. Accessed June 9, 2025. https://www.zeiss.com/meditec/en/products/retinal-cameras/clarus-700.html

3. ZEISS Glaucoma Workplace. ZEISS. Accessed June 9, 2025. https://www.zeiss.com/meditec/en/products/data-management-software/glaucoma-workplace.html